Overview

Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)

Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety of UX053 in adults with Glycogen Storage Disease Type III (GSD III).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ultragenyx Pharmaceutical Inc
Treatments:
Acetaminophen
Antipyretics
Cetirizine
Famotidine
Ibuprofen